GlassScriptPhysician profile
Mohsin I Malik
NPI 1366588816
$12,233.03
in general payments reported to CMS, 2019-2025
67 companies · $1,024 in 2025
The $1,024 reported for 2025 was less than what a typical Medical Oncology provider received nationally (typical 2025 total: $1,158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $821 · 2020: $241 · 2021: $751 · 2022: $1,823 · 2023: $3,024 · 2024: $4,550 · 2025: $1,024.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,259 · Education: $674 · Long Term Medical Supply Or Device Loan: $665.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,258.74 |
| Education | $673.89 |
| Long Term Medical Supply Or Device Loan | $665.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,459.77 | 2019-2025 | |
| Celgene Corporation | $1,191.99 | 2019-2025 | Reblozyl, Opdualag, Pomalyst |
| Janssen Biotech, INC. | $1,040.42 | 2019-2025 | Tremfya, Darzalex, Talvey |
| Pfizer INC. | $620.08 | 2019-2025 | |
| Astellas Pharma US INC | $582.88 | 2021-2025 | Padcev, Vyloy, Xtandi |
| Merck Sharp & Dohme LLC | $578.85 | 2022-2025 | Keytruda, Lynparza, Welireg |
| Daiichi Sankyo INC. | $457.90 | 2019-2025 | Enhertu, Vanflyta, Datroway |
| E.R. Squibb & Sons, L.L.C. | $370.92 | 2019-2024 | Opdivo, Opdualag, Krazati |
| Eisai INC. | $370.66 | 2021-2025 | |
| Gilead Sciences, INC. | $361.19 | 2022-2025 | Trodelvy |
| Genzyme Corporation | $345.68 | 2020-2024 | |
| Glaxosmithkline, LLC. | $259.90 | 2020-2024 | Jemperli, Ojjaara, Zejula |
| Amgen INC. | $255.37 | 2019-2023 | Nplate, Xgeva, Vectibix |
| Seagen INC. | $227.57 | 2022-2023 | Adcetris, Tukysa, Tivdak |
| Genentech USA, INC. | $215.82 | 2020-2024 | Tecentriq, Venclexta, Perjeta |
Show all 67 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $215.72 | 2019-2024 | Enhertu, Lynparza, Imfinzi |
| Abbvie INC. | $206.36 | 2022-2025 | |
| Incyte Corporation | $205.29 | 2024-2025 | Jakafi, Monjuvi, Pemazyre |
| Lilly USA, LLC | $204.56 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Bayer Healthcare Pharmaceuticals INC. | $200.93 | 2019-2024 | |
| Sobi, INC | $196.11 | 2022-2025 | |
| Octapharma USA, INC. | $180.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $172.34 | 2022-2025 | Alunbrig, Hyqvia, Fruzaqla |
| Regeneron Healthcare Solutions, INC. | $137.78 | 2022-2025 | Libtayo, Dupixent |
| Pharmacosmos Therapeutics INC. | $133.75 | 2023-2025 | Monoferric, Cosela |
| Array Biopharma INC | $123.78 | 2020-2024 | Lorbrena, Braftovi, Mektovi |
| Beigene USA, INC. | $117.90 | 2021-2024 | Brukinsa |
| Tersera Therapeutics LLC | $115.55 | 2023-2024 | Zoladex |
| Mayne Pharma Commercial LLC | $97.63 | 2019 | |
| Kite Pharma, INC. | $96.78 | 2022-2025 | Yescarta |
| Jazz Pharmaceuticals INC. | $95.94 | 2022-2024 | |
| Pharmaessentia USA Corporation | $92.69 | 2023-2025 | Besremi |
| Stemline Therapeutics INC. | $83.54 | 2023-2025 | Orserdu |
| Emd Serono, INC. | $82.35 | 2023-2024 | Bavencio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $77.99 | 2020-2021 | |
| Clovis Oncology, INC. | $72.94 | 2019 | |
| Alexion Pharmaceuticals, INC. | $72.04 | 2019-2024 | Ultomiris |
| Pharmacyclics LLC, An Abbvie Company | $70.77 | 2021-2023 | Imbruvica |
| Global Blood Therapeutics, INC. | $61.74 | 2020-2022 | |
| Agios Pharmaceuticals, INC. | $57.57 | 2023-2024 | Pyrukynd |
| Puma Biotechnology, INC. | $52.66 | 2022-2024 | |
| Karyopharm Therapeutics INC. | $52.26 | 2022-2024 | Xpovio |
| Sumitomo Pharma America, INC. | $43.15 | 2024 | Orgovyx |
| Alnylam Pharmaceuticals INC. | $43.13 | 2022-2023 | Givlaari |
| Blueprint Medicines Corporation | $40.04 | 2023 | Ayvakit |
| Adc Therapeutics America, INC. | $36.56 | 2024-2025 | |
| Taiho Oncology, INC. | $35.67 | 2024-2025 | |
| Springworks Therapeutics, INC. | $34.18 | 2024-2025 | Ogsiveo |
| Csl Behring | $33.52 | 2021-2024 | Idelvion, Afstyla |
| Ucb, INC. | $29.04 | 2020 | |
| Immunogen, INC. | $27.00 | 2023 | Elahere |
| Apellis Pharmaceuticals, INC. | $22.23 | 2023 | Empaveli |
| Myriad Genetic Laboratories, INC. | $21.86 | 2024 | Myrisk |
| Morphosys, US INC. | $21.48 | 2022 | |
| Mirati Therapeutics, INC. | $20.24 | 2024 | Krazati |
| Eusa Pharma (US) LLC | $19.69 | 2022 | |
| Recordati_rare_diseases_inc. | $19.68 | 2022 | |
| Exelixis INC. | $19.46 | 2025 | Cabometyx |
| Myovant Sciences INC. | $18.93 | 2022 | |
| Cti Biopharma Corp. | $18.56 | 2023 | Vonjo |
| Coherus Oncology, INC. | $18.49 | 2025 | Loqtorzi |
| Tempus Ai, INC | $18.35 | 2024 | Xt Cdx |
| Sirtex Medical INC | $17.33 | 2020 | |
| Servier Pharmaceuticals LLC | $16.24 | 2024 | |
| Ipsen Biopharmaceuticals, INC | $14.28 | 2019 | |
| Secura Bio, INC. | $14.01 | 2022 | |
| Legend Biotech USA INC. | $13.94 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohsin Malik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.